Research programme: siRNA therapeutics - PreveCeutical Medical/UniQuest

Drug Profile

Research programme: siRNA therapeutics - PreveCeutical Medical/UniQuest

Alternative Names: Dual gene therapy - PreveCeutical/UniQuest

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PreveCeutical Medical; UniQuest
  • Developer Murdoch University; PreveCeutical Medical; QIMR Berghofer Medical Research Institute; UniQuest
  • Class Antihyperglycaemics; Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetes mellitus; Obesity

Most Recent Events

  • 26 Jul 2017 PreveCeutical Medical enters into a research and option agreement with UniQuest for development of siRNAs for Diabetes mellitus and Obesity
  • 13 Apr 2017 Early research in Obesity and Diabetes mellitus in USA (Parenteral)
  • 13 Apr 2017 Early research in Obesity and Diabtes mellitus in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top